Hikma Pharmaceuticals PLC (Hikma) said that its venture capital arm, Hikma Ventures Limited (Hikma Ventures) has invested in Biolinq, the next generation minimally-invasive biosensor technology company, in collaboration with M Ventures which led the $10 million series A round of financing.
Lana Ghanem, managing director of Hikma Ventures and Edward Kliphuis, investment director of the new businesses fund at M Ventures will be joining the Biolinq board of directors.
Biolinq is a digital health company with a unique, wirelessly-enabled biosensor patch that is capable of continuously monitoring multiple biomarkers. Biolinq’s first commercial product, a unique minimally-invasive technology will allow patients with diabetes to continuously monitor their blood glucose without the pain and hassle of traditional continuous glucose monitoring (CGM) systems.
“Diabetes is a chronic disease affecting millions of people worldwide with a high prevalence in the Middle East and North Africa. We enjoyed working alongside the M Ventures team on closing this investment and we look forward to working with the Biolinq team and our other co-investors to bring this technology to patients,” said Lana Ghanem.
Read More: Hikma invests in digital health firm Biolinq
No comments:
Post a Comment